Kymera Therapeutics, Inc. Common Stock

KYMRNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
116.11 USD
↗ 2.96 (2.61%)🟢LIVE (AS OF 12:07 PM EDT)
🟢Market: OPEN

KYMR is currently priced at $116.11. Our models show a "Neutral" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, KYMR is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Sep 15, 2026.

Open?$113.06
High?$116.84
Low?$102.19
Prev. Close?$113.15
Volume?185.7K
Avg. Volume?679.6K
VWAP?$115.62
Rel. Volume?0.27x
Bid / Ask
Bid?$99.78 × 100
Ask?$132.85 × 100
Spread?$33.07
Midpoint?$116.32
Valuation & Ratios
Market Cap?9.4B
Shares Out?83.2M
Float?59.6M
Float %?71.7%
P/E Ratio?N/A
P/B Ratio?6.23
EPS?-$3.60
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Themes
Biotech - Drug Development›Clinical-Stage PlatformsHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
273
Market Cap
9.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.kymeratx.com
Listed
2020-08-21
Address
500 NORTH BEACON STREET, 4TH FLOOR
WATERTOWN, MA 02472
Phone: 857-285-5314
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
83
Short Sent.?
39
Piotroski F-Score?4/9Mixed
Altman Z-Score?40.28Safe
Confidence?62%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?17.40%High
Short Interest?10.4M
Days to Cover?16.8
Free Float59.6M
Avg Daily Volume616.3K
Settlement Date2026-08-31
Financial Health
Current Ratio?10.34Strong
Quick Ratio?10.34Strong
Cash Ratio?1.75Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
29
6.23FAIR▾
P/S?
Peers
100
S&P
3
89.61HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-27.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
88.44HIGH▾
Returns & Efficiency
ROE?
S&P
8
-19.9%WEAK▾
ROA?
S&P
3
-18.2%WEAK▾
Cash Flow & Enterprise
FCF?$-237956000
Enterprise Value?$9.3B
Fundamentals ratios updated end of day
MarketsMoversWatchlist